Arvinas Inc.
Clinical trials sponsored by Arvinas Inc., explained in plain language.
Arvinas Inc.
ARVN
NASDAQ
Biopharmaceutical company developing targeted protein degradation therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug targets Hard-to-Treat cancer mutation in first human trial Results expected Nov 2026 (estimated)